Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Carlyle Group Inc (CG) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Carlyle Group IncTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Carlyle Group Inc vs Neurocrine Biosciences Inc — how do they compare? Carlyle Group Inc trades at $47.53 (market cap $17.23B), while Neurocrine Biosciences Inc trades at $158.62 (market cap $16.46B). The key difference: Carlyle Group Inc and Neurocrine Biosciences Inc are close in size by market cap, and Carlyle Group Inc pays a 2.9% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

CGNBIX
Market Cap
$17.23B$16.46B
Sector
FinancialsHealth
52-Week High
$69.35$185.50
52-Week Low
$40.52$123.10
Dividend Yield
2.9%
Enterprise Value
$16.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Carlyle Group Inc

CG trades at $47.80, up 0.02% daily, with a bullish technical signal from moving averages and a consensus analyst price target of $59.14. Recent Q2 2026 earnings beat expectations, with EPS of $1.07 versus $0.91 expected, while revenue trends show volatility, declining to $2.8B in 2026 from $3.2B in 2025. The company maintains a dividend of $0.35 per share and has strong institutional interest, with 53.84% of analysts rating it a Buy.

The outlook for CG is positive due to earnings beats and analyst optimism, but risks include inconsistent cash flow from operations and declining revenue. Investment opportunity lies in potential upside to the price target, supported by fundraising strength and strategic partnerships, though investors should monitor execution risks and macroeconomic pressures.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Carlyle Group Inc

The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.

Read more on CG

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX